职业治疗主导的自管理支持项目用于多病共存基层保健的成本效果
本研究基于一项纳入149名多病共存成人的随机对照试验,从医疗保健视角开展经济评价,比较为期6周的职业治疗主导自管理支持项目(OPTIMAL)与常规基层保健。结果显示干预组每患者平均QALY增益0.031(P=0.063;95%CI -0.002至0.063),总成本平均降低2548欧元(P=0.114;95%CI -5606至509),在每QALY 20000欧元和45000欧元阈值下具有成本效果的概率分别为0.951和0.958。
要点
- OPTIMAL项目每患者QALY增益0.031,总成本降低2548欧元,但差异均未达统计学显著。
- 在每QALY 20000欧元和45000欧元阈值下,成本效果概率分别为0.951和0.958。
- 亚组分析结果一致,但研究样本量有限,需进一步验证。
核心结论
- OPTIMAL项目在多病共存成人中可能具有成本效果,但QALY增益和成本降低的统计学不确定性较大。
研究设计与样本
- 基于149名多病共存成人的随机对照试验开展的经济评价,从医疗保健视角分析,干预为6周职业治疗主导自管理支持项目(OPTIMAL),对照为常规基层保健。
主要发现
- 干预组每患者平均QALY增益0.031(P=0.063;95%CI -0.002至0.063)。
- 干预组每患者总成本平均降低2548欧元(P=0.114;95%CI -5606至509)。
- 在每QALY 20000欧元和45000欧元阈值下,成本效果概率分别为0.951和0.958。
- 所有 examined 亚组结果保持一致。
关键数值与推荐
- 成本效果阈值每QALY 20000欧元时,成本效果概率0.951。
- 成本效果阈值每QALY 45000欧元时,成本效果概率0.958。
临床怎么用
- 基层可考虑为多病共存成人提供职业治疗主导的短期自管理支持项目,但需结合本地成本效果阈值评估。
局限性
- 样本量较小(149人),QALY增益和成本差异未达统计学显著。
- 随访时间仅6个月,长期成本效果未知。
- 需进一步研究复杂干预在多病共存患者及其亚组中的临床和成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multimorbidity is a major public health concern. Complex interventions, incorporating individualized care plans, may be appropriate for patients with multimorbidity given their individualized and variable needs. There is a dearth of evidence on the cost-effectiveness of complex multimorbidity interventions. OBJECTIVE: This study examines the cost-effectiveness of a 6-week occupational therapy-led self-management support programme (OPTIMAL) for adults with multimorbidity. METHODS: Economic evaluation, from a healthcare perspective, was conducted alongside a randomized controlled trial of 149 adults with multimorbidity. Intervention was the OPTIMAL programme with a comparison of usual primary care. Incremental costs, quality-adjusted life years (QALYs) gained, and expected cost-effectiveness were estimated at 6 months and uncertainty was explored using cost-effectiveness acceptability curves. RESULTS: The intervention was associated with a mean improvement in QALYs gained of 0.031 per patient (P-value: 0.063; 95% confidence intervals [CIs]: -0.002 to 0.063) and a mean reduction in total costs of €2,548 (P-value: 0.114; 95% CIs: -5,606 to 509) per patient. At cost-effectiveness threshold values of €20,000 and €45,000 per QALY, the probability of the intervention being cost-effective was estimated to be 0.951 and 0.958, respectively. The results remained consistent across all subgroups examined. CONCLUSIONS: This study adds to the limited evidence base on the cost-effectiveness of complex interventions for multimorbidity, and highlights the potential for the OPTIMAL programme to be cost-effective. Further studies are warranted to explore the clinical and cost-effectiveness of complex interventions for the multimorbidity patient population, and for subgroups within it. TRIAL REGISTRATION: Trial number: ISRCTN67235963.
引用
- Gillespie P, Hobbins A, O'Toole L, et al. Cost-effectiveness of an occupational therapy-led self-management support programme for multimorbidity in primary care. Fam Pract. 2022. PMID: 35137039. doi:10.1093/fampra/cmac006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。